Biovisu Rallies on Expanded U.S. Push and Growing Expectations for Skin Booster Business

As Biovisu begins to actively target the U.S. market with its medical cosmetic brand, expectations for the expansion of its skin booster business are growing, resulting in a strong performance during intraday trading.

As of 3:09 p.m. on July 21, Biovisu was trading at 7,750 won, up 23.64% from the previous day.

The company is accelerating its expansion into the North American market by securing entry for its medical cosmetic brand 'Candorlov (CANDORLOV·CDL)' into a U.S. pharmacy chain. Candorlov is a brand offering a diverse range of basic skincare products, including mask packs, serums, ampoules, toner pads, mists, and creams.

The United States has recently emerged as a key market for K-beauty. Last year, for the first time, exports of Korean cosmetics to the United States surpassed those to China, making the U.S. the largest export destination and further boosting the market's growth potential. Biovisu is expanding both its online and offline distribution channels to strengthen its strategy for the North American market.

The company is also securing growth drivers in the medical aesthetic sector. Most recently, it obtained exclusive domestic distribution rights for 'Cellivion,' a skin booster brand based on human acellular dermal matrix (hADM) and extracellular matrix (ECM). This has broadened its product portfolio. ECM-based skin boosters are gaining significant attention as next-generation aesthetic products, with a focus on skin regeneration and elasticity improvement.

The filler brand 'Colena (COLENA)' is also seen as a strong growth business. After receiving domestic product approval in March, the company established a foundation to expand its OEM (Original Equipment Manufacturer) production base. It is expected that obtaining European CE certification and China's National Medical Products Administration (NMPA) certification in the future will accelerate overseas market expansion.

Currently, Biovisu supplies its products to over 10 countries, including China, and is expanding sales channels from its existing Chinese distribution network to the North American and other global markets.

Industry experts observe that the global medical aesthetics market is steadily growing, particularly driven by fillers and skin boosters. As a result, companies with comprehensive capabilities in research and development, production, and global distribution are expected to stand out competitively.

An industry insider commented, "The global aesthetics market is rapidly expanding, centered around high-functionality fillers and skin boosters. Biovisu is recognized as a company with high growth potential, having established its own value chain from research and development to production and global distribution."

Biovisu is a medical aesthetics specialist engaged in the research, development, and production of skin boosters and fillers utilizing hyaluronic acid and various bio-based ingredients. Currently, its annual production capacity stands at approximately 2.64 million units, with plans to increase capacity to about 8.64 million units upon completion of its second factory.

The company also plans to further enhance its competitiveness in the global medical aesthetic market by developing new products using next-generation bio-materials such as lipid nanoparticles (LNP) and exosomes and diversifying its product lines.

This content was produced with the assistance of AI translation services.